Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686152 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 589
- Enrollment target
NCT01686152: Completed Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT01686152 is a Phase 3 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 589 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01686152, a Phase 3 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 589 participants
- Enrollment target
Study Summary
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp. It will also be determined whether the efficacy of each of the two active treatments is superior to that of the Vehicle cream.
Interventions
- DRUG Zyclara®
- DRUG Imiquimod Cream, 3.75%
- OTHER Vehicle of Test Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686152
The ClinicalTrials.gov registry entry for NCT01686152 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 589 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zyclara® is the first listed.
NCT01686152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686152 about?
NCT01686152 is a clinical study titled "Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis". To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp. It will also be determined whether the efficacy of each of the two active treatme...
What is the current status of trial NCT01686152?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 589 participants. The study started on 2012-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01686152?
The interventions under investigation include: Zyclara® (DRUG), Imiquimod Cream, 3.75% (DRUG), Vehicle of Test Product (OTHER).
Who is sponsoring clinical trial NCT01686152?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.